Ustekinumab therapy for moderately to severely active pediatric Crohn's disease: UNITI Jr study safety and efficacy results in patients weighing at least 40 kg.
Primary infliximab failure in pediatric colonic inflammatory bowel disease: Development of a proteomics predictive model using a prospective Canadian cohort.
Asthma and inhaled corticosteroids in primary ciliary dyskinesia (PCD): A consensus from the Minneapolis PCD meeting.
Efficacy, Safety, and Pharmacokinetics of Golimumab in Children with Moderately-To-Severely Active Ulcerative Colitis: Results from the PURSUIT 2 Study.
Preclinical stages of Crohn’s disease defined by faecal calprotectin in asymptomatic first-degree relatives: screening framework for prevention trials
North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition position paper on the therapeutic drug monitoring in pediatric inflammatory bowel disease.
Metabolomics reveal distinct molecular pathways associated with future risk of Crohn’s Disease
Metabolomics reveal distinct molecular pathways associated with future risk of Crohn's Disease.
Perspectives of Adolescents and Young Adults With Inflammatory Bowel Disease on a Biopsychosocial Transition Intervention: Qualitative Interview Study.
P1059 Fecal calprotectin response to Tasty&Healthy dietary intervention in asymptomatic children and young adults with biologically active Crohn’s disease: results of the “TASTI-E” randomized controlled trial
Perspectives of Adolescents and Young Adults With Inflammatory Bowel Disease on a Biopsychosocial Transition Intervention: Qualitative Interview Study
Linking microbial genes to plasma and stool metabolites uncovers host-microbial interactions underlying ulcerative colitis disease course
Environmental Factors Associated With Risk of Crohn’s Disease Development in the Crohn’s and Colitis Canada - Genetic, Environmental, Microbial Project
Machine Learning–Based Prediction of Pediatric Ulcerative Colitis Treatment Response Using Diagnostic Histopathology
Environmental Factors Associated With Risk of Crohn's Disease Development in the Crohn's and Colitis Canada - Genetic, Environmental, Microbial Project.
Primary sclerosing cholangitis in children with inflammatory bowel disease: An ESPGHAN position paper from the Hepatology Committee and the IBD Porto group
Ustekinumab in paediatric patients with moderately to severely active Crohn's disease: UniStar study long‐term extension results
Outcomes Following Acute Severe Colitis at Initial Presentation: A Multi-centre, Prospective, Paediatric Cohort Study.
Adalimumab vs Infliximab in Luminal Pediatric Crohn's Disease: Comparable Outcomes in a Prospective Multicenter Cohort Study.
Landscape of TPMT and NUDT15 Pharmacogenetic Variation in a Cohort of Canadian Pediatric Inflammatory Bowel Disease Patients.
Pre-Diagnosis Diet Predicts Response to Exclusive Enteral Nutrition and Correlates with Microbiome in Pediatric Crohn Disease.
Outcomes and Endpoints of Postoperative Recurrence in Crohn's Disease: Systematic Review and Consensus Conference.
Serum Metabolites Relate to Mucosal and Transmural Inflammation in Paediatric Crohn Disease
Serum Metabolites Relate to Mucosal and Transmural Inflammation in Paediatric Crohn Disease.
Recommendations for Broadening Eligibility Criteria in Inflammatory Bowel Disease Clinical Trials.
Response from the Canadian Children Inflammatory Bowel Disease Network to the US Food and Drug Administration Draft Guidance for Industry on pediatric inflammatory bowel disease: developing drugs for treatment.
Outcomes in Adult Inflammatory Bowel Disease Clinical Trials: Assessment of Similarity Among Participants with Adolescent-onset and Adult-onset Disease
Serological Markers as Predictors of Anti-TNF Response in Children with Crohn’s Disease
Outcomes in Adult Inflammatory Bowel Disease Clinical Trials: Assessment of Similarity Among Participants with Adolescent-onset and Adult-onset Disease.
Gut Microbiome Composition Is Associated With Future Onset of Crohn’s Disease in Healthy First-Degree Relatives